Rahimy E, et al. - Authors assessed the safety and impacts of oral eplerenone in chronic central serous chorioretinopathy. With respect to anatomic changes, in the eplerenone group mean maximal subretinal fluid height improved from 139.3 μm at baseline to 51.8 μm, mean subfoveal fluid height improved from 121.4 μm to 29.4 μm, and mean central subfield thickness improved from 366.2 μm to 283.7 μm. They noted that in the treatment of chronic central serous chorioretinopathy with persistent subretinal fluid, the oral eplerenone therapy was safe and potentially effective.